Melatonin and urological cancers: a new therapeutic approach

Cancer Cell International

Kobra Bahrampour Juybari¹  Azam Hosseinzadeh²  Saeed Mehrzadi²  Mohammad Hossein Pourhanifeh³ 

[1] Department of Pharmacology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran;Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran;Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran;

关键词: Bladder cancer;    Prostate cancer;    Renal cell carcinoma;    Melatonin;    Chemotherapy;    Radiotherapy;    Urological cancers;    Angiogenesis;    Apoptosis;    Autophagy;    Oxidative stress;    Inflammation;    metastasis;   

DOI  :  10.1186/s12935-020-01531-1

来源: Springer

【 摘 要 】

Urological cancers are responsible for thousands of cancer-related deaths around the world. Despite all developments in therapeutic approaches for cancer therapy, the absence of efficient treatments is a critical and vital problematic issue for physicians and researchers. Furthermore, routine medical therapies contribute to several undesirable adverse events for patients, reducing life quality and survival time. Therefore, many attempts are needed to explore potent alternative or complementary treatments for great outcomes. Melatonin has multiple beneficial potential effects, including anticancer properties. Melatonin in combination with chemoradiation therapy or even alone could suppress urological cancers through affecting essential cellular pathways. This review discusses current evidence reporting the beneficial effect of melatonin in urological malignancies, including prostate cancer, bladder cancer, and renal cancer.

【 授权许可】

CC BY